Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Brimapitide (Primary)
- Indications Sensorineural hearing loss
- Focus Registrational; Therapeutic Use
- Acronyms ASSENT
- Sponsors Auris Medical
- 08 Dec 2017 Planned End Date changed from 1 Jun 2018 to 1 Mar 2018.
- 08 Dec 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Mar 2018.
- 08 Dec 2017 Status changed from recruiting to active, no longer recruiting.